Stay updated on FT538 with Daratumumab in AML Clinical Trial
Sign up to get notified when there's something new on the FT538 with Daratumumab in AML Clinical Trial page.

Latest updates to the FT538 with Daratumumab in AML Clinical Trial page
- Check3 days agoChange DetectedNew versions in the record history show updates to Study Status and Recruitment Status. The changes reflect the trial’s evolving state and its enrollment status.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check32 days agoChange DetectedNew operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.SummaryDifference12%

- Check39 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.3%

- Check53 days agoChange DetectedUpdated revision to v3.0.2 and removed the Back to Top link; no changes to core content, pricing, stock, or time slots.SummaryDifference0.7%

- Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.7%

- Check67 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while several location-related terms have been removed.SummaryDifference16%

Stay in the know with updates to FT538 with Daratumumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FT538 with Daratumumab in AML Clinical Trial page.